Serina therapeutics, inc.SER.US Overview

US StockHealthcare

(No presentation for SER)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

SER Overall Performance

SER AI Analysis & Strategy

SER Recent Performance

3.97%

Serina therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

SER PowerScanner

SER Key Information

SER Valuation Metrics

SER Earnings Table

SER Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.